Mirati Therapeutics, Inc. (NASDAQ: MRTX) announced that positive preliminary data from two ongoing clinical trials of sitravatinib in non-small cell ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE